Skip to main content
TipRanks
Go Ultimate75% OFF

Arcturus Therapeutics (ARCT) Stock Price & Analysis

2,165 Followers

ARCT Stock Chart & Stats

$8.36-$0.08(-0.95%)
At close: 4:00 PM EST
$7.5$10$12.5$15Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$8.12 - $8.68
52-Week Range
$5.50 - $17.96
Previous Close
$8.44
Volume
N/A
Average Volume (3M)
688.59K
Market Cap
$240.96M
Enterprise Value
$226.39M
Total Cash (Recent Filing)
$184.82M
Total Debt (Recent Filing)
$21.86M
Price to Earnings (P/E)
―
Beta
2.26
Next Earnings
Mar 11, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving MRNA Delivery Platform

The reported potency improvement could enable lower or less frequent dosing and expand the diseases addressable with mRNA medicines. If translated clinically, stronger delivery performance may reinforce Arcturus’s technology differentiation and support multiple future programs.

Clinical Pipeline Advancement

Positive ARCT-810 biomarker results, alongside planned ARCT-2601 Phase II dosing, provide evidence of progress across the rare-disease pipeline. Advancing multiple programs can diversify clinical catalysts and improve the company’s ability to convert platform capabilities into therapies.

Extended Funding Runway

A cash runway through 2028 gives Arcturus time to reach several clinical and regulatory milestones without an immediately indicated financing need. This supports continued investment in the pipeline and provides flexibility while programs generate data and partnership opportunities.

Bears Say

Persistent Cash-burning Losses

Negative operating and free cash flow show that the current business is not self-funding. Continued clinical investment therefore consumes capital, and prolonged losses could eventually reduce financial flexibility or require additional funding before products generate recurring revenue.

Sharp Revenue Contraction

The steep revenue decline highlights the volatility of Arcturus’s collaboration and grant-driven revenue model. Lower recognized revenue reduces near-term operating support and underscores that future financial performance depends heavily on new milestones, partnerships, or successful commercialization.

Uncertain ARCT-032 Phase III Timing

Uncertainty around the Phase III start delays clarity on the development path for a key cystic-fibrosis program. Additional data analysis and FDA engagement are still required, which could extend timelines, postpone potential partnership contributions, and defer any future product revenue.

Arcturus Therapeutics News

ARCT FAQ

What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.50 and its highest was $17.96 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $240.96M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 115 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.687 by $0.427.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a dividend of $0.06 which represents an annual dividend yield of ―. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.82.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,822,514 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.687. Following the earnings report the stock price went up 10.577%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Hedge funds hold Arcturus Therapeutics shares: the largest hedge-fund position in Arcturus Therapeutics is 70,138,975 shares, and hedge funds increased their holdings by 132.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology